Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | GUCY1A1 | Q02108 | 13/20 | 0.48 |
| ▸ | GUCY1B1 | Q02153 | 13/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC26A6 | Q9BXS9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17517361 | 0.91 | KCNH2 (0.50) | KCNH2ADORA3GUCY1A1GUCY1B1LMNA | |
| SCHEMBL17517359 | 0.86 | KCNH2 (0.45) | KCNH2ADORA3GUCY1A1GUCY1B1AURKA | |
| SCHEMBL17517365 | 0.86 | KCNH2 (0.40) | KCNH2ADORA3GUCY1A1GUCY1B1 | |
| SCHEMBL22874060 | 0.83 | AURKA (0.43) | LMNAAURKARPS6KB1SMN1; SMN2SLC26A6 | |
| SCHEMBL24555972 | 0.82 | GUCY1A1 (0.47) | KCNH2ADORA3GUCY1A1GUCY1B1SMN1; SMN2 | |
| SCHEMBL17517367 | 0.82 | KCNH2 (0.41) | KCNH2ADORA3GUCY1A1GUCY1B1AURKA | |
| SCHEMBL17517358 | 0.81 | KCNH2 (0.40) | KCNH2ADORA3GUCY1A1GUCY1B1 | |
| SCHEMBL15987095 | 0.80 | LMNA (0.38) | KCNH2ADORA3LMNAAURKARPS6KB1 | |
| SCHEMBL19146434 | 0.80 | LMNA (0.35) | KCNH2ADORA3LMNAAURKARPS6KB1 | |
| SCHEMBL17517357 | 0.79 | GUCY1A1 (0.43) | KCNH2ADORA3GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160122347-A1 | 4,6-DIAMINOPYRIMIDINE STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | AUSPEX PHARMACEUTICALS INC (US) | 2016-05-05 | — | — | US | disclosed |
| US-9260424-B2 | 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122347-A1 | 4,6-DIAMINOPYRIMIDINE STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | GUCY1B2, GUCY1A2, GUCY1A1 | KCNH2 1463/4885ADORA3 191/4885GUCY1A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.